EiRx THERAPEUTICS (ERX): CHART AND DISCUSSION THREAD (moderated)

Eirx Therapeutics EiRx Therapeutic full year pretax narrows to 3 mln stg from 2 mln


LONDON (AFX) - EiRx Therapeutics PLC full year pretax loses narrowed to 3
mln stg from 2 mln last year.
The drug discovery company developing targeted therapies for cancer reported
turnover of 27,000 stg from 69,000 last year, predominantly from its acquisition
of Auvation which accounted for revenues and royalty income for the year.
The company added that it will need to raise further capital to fund the
development of hit compounds and exploit its tissue bank resource.